statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire AUSTIN, Texas, June 27, 2024 Company Achieves...

Genprex to Present at the 2024 BIO International Convention

Genprex to Present at the 2024 BIO International Convention Genprex to Present at the 2024 BIO International Convention PR Newswire AUSTIN, Texas, May 30, 2024 Presentation to Highlight the Company's...

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer Genprex Doses First Patient in Acclaim-3 Clinical...

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors PR...

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner PR Newswire...

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences Genprex to Present and Participate at Upcoming May Investor and Industry Conferences PR Newswire AUSTIN, Texas...

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR...

Genprex (NASDAQ:GNPX) Receives "Buy" Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Genprex (NASDAQ:GNPX - Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a $10.00...

Genprex, Inc. to Post Q1 2025 Earnings of ($0.86) Per Share, HC Wainwright Forecasts (NASDAQ:GNPX)

Genprex, Inc. (NASDAQ:GNPX - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Genprex in a research report issued on Wednesday, April 3rd. HC...

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer Genprex Expands Clinical Trial Sites for Acclaim-3...

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Volume	15,372.00
52-Wk High	$31.00
52-Wk Low	$1.77

GNPX Genprex Inc

About

Feed

News

Sentiment

Earnings

Fundamentals